PULMONARY VASCULAR TOXICITY WITH TYROSINE KINASE INHIBITOR THERAPY: A RARE CASE IN A CHRONIC MYELOID LEUKEMIA PATIENT

Nicole Prabhu(University of Chicago), Jeanne M. DeCara(University of Chicago), Wendy Stock(University of Chicago), Eisha Wali(University of Chicago Medical Center), Sean Pinney(University of Chicago)

JACC CardioOncology

February 15, 2022

10.1016/j.jaccao.2022.01.088

Cited by 1

Related Papers

<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

|New England Journal of Medicine|2016|783

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia

|Nature Genetics|2019|616

Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study

|The Lancet Oncology|2020|370

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study

|Cancer|2019|327

Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia

|JAMA Oncology|2018|168